Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

David P. Serota, Emory University
Harold Franch, Emory University
Emily Jeanne Cartwright, Emory University

Journal Title: Open Forum Infectious Diseases
Volume: Volume 5, Number 8
Publisher: Oxford University Press (OUP) | 2018-08-01, Pages ofy189-ofy189
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofy189
Permanent URL: https://pid.emory.edu/ark:/25593/t5b9f

Final published version: http://dx.doi.org/10.1093/ofid/ofy189

Copyright information:
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed December 14, 2022 2:52 PM EST
Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

David P. Serota,1 Harold A. Franch,2,3 and Emily J. Cartwright1,2

1Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia; 2Atlanta VA Medical Center, Veterans Health Administration, Atlanta, Georgia; 3Division of Renal Medicine, Department of Medicine, Emory University, Atlanta, Georgia

HIV treatment with tenofovir alafenamide fumarate (TAF) has decreased renal toxicity compared with tenofovir disoproxil fumarate in clinical trials. We report the case of a patient with HIV/HCV coinfection who was started on a TAF-based HIV regimen and developed acute kidney injury that worsened with the addition of sofosbuvir-ledipasvir.

Keywords. acute kidney injury; hepatitis C; HIV infection; tenofovir alafenamide.

The advent of hepatitis C virus (HCV) direct-acting antivirals (DAAs) has drastically improved the prognosis for those living with HCV infection. This is of particular importance for patients coinfected with HIV as they have higher rates of HCV complications including cirrhosis, hepatocellular carcinoma, and extrahepatic organ dysfunction [1, 2]. As access to DAAs has expanded, treatment of HCV in coinfected patients is a priority [3]. Persons with HIV/HCV coinfection show similar efficacy and tolerability when treated with DAAs [4, 5].

The American Association for the Study of Liver Diseases (AASLD)–Infectious Diseases Society of American (IDSA) HCV guidelines recommend consulting a resource like the University of Liverpool’s website (www.hep-druginteractions.org) to explore drug interactions before initiating HCV treatment. Ledipasvir (LED) is an HCV NS5A inhibitor formulated with sofosbuvir (SOF), a nucleotide analogue NS5B polymerase inhibitor, and administered once daily as a fixed-dose combination tablet (SOF/LED). Administration of SOF/LED with tenofovir disoproxil fumarate (TDF) and ritonavir or cobicistat can lead to elevated TDF exposure and is not recommended [6].

Tenofovir alafenamide (TAF) was approved for HIV treatment in the United States in 2015. Compared with tenofovir disoproxil fumarate, TAF has an improved side effect profile and higher intracellular drug levels [7]. In phase III clinical trials comparing TAF- and TDF-based regimens, TAF-based treatment demonstrated improved renal and bone mineral density outcomes [8]. There have been few reported renal adverse events related to TAF; however, clinical trial participants lacked HCV co-infection [9]. There is no expected interaction between SOF/LED and TAF, and co-administration is encouraged.

We present the case of an older man with HIV/HCV coinfection with decompensated cirrhosis who developed acute kidney injury a few months after starting tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat (EVT/c/FTC/TAF), with the addition of SOF/LED. This case demonstrates potentially unreported risks of renal morbidity attributable to the combination of these medications in a frail patient.

CASE PRESENTATION

A 70-year-old man with HIV-1 infection, alcohol use disorder, chronic HCV infection, and Childs-Turcott-Pugh class B cirrhosis initially presented to establish HIV care in December 2016 (Figure 1). He was started on dolutegravir-abacavir-lamivudine (DTG/ABG/3TC) but was changed to EVG/c/FTC/TAF in February 2017 due to perceived neuropsychiatric side effects [10]. At the time of initiation of therapy, his HIV viral load was >1 million copies/mL and his absolute CD4 helper T-cell count was 100 cells/mL, with a CD4 percentage of 9%. He was diagnosed with HCV infection 12 years before presentation. He had a history of decompensated cirrhosis; his HCV was genotype 1b, and his viral load was 13,300,000 IU/mL. In February 2017, his serum creatinine level was 1.2 mg/dL, with an estimated creatinine clearance of 50 mL/min (using the Cockcroft-Gault equation). One month after initiating EVG/c/FTC/TAF, his serum creatinine increased to 1.65 mg/dL, with normal electrolyte levels. At the time, this increase was attributed to decreased excretion of creatinine associated with cobicistat initiation.

Treatment for his HCV infection was initiated with SOF/LED on May 1, 2017, for a planned 24-week duration based on IDSA/AASLD HCV guidelines for treatment-naive patients with class B cirrhosis [3]. On May 17, he had a follow-up clinic appointment, at which time his serum creatinine had increased to 2.46 mg/dL with otherwise normal electrolyte levels. On May 22, his blood pressure was 128/89 mmHg, and he was euovolemic on examination. Spironolactone and furosemide were stopped...
He was started on an infusion of sodium bicarbonate, and both his HIV and HCV medications were temporarily discontinued. He was nonoliguric throughout his hospital stay. His serum creatinine improved to 1.91 mg/dL on hospital day 6. Features of proximal renal tubular acidosis, including elevated fractional excretion of phosphate (40%) and persistently low serum bicarbonate, were observed. He was transitioned to oral sodium bicarbonate and started on DTG/ABC/3TC, and his HCV therapy was changed to sofosbuvir-daclatasvir (SOF-DAC) given concern for reduced ledipasvir absorption in the setting of increased gastric pH from the sodium bicarbonate. Twelve weeks after hospital discharge, his creatinine was 1.32 mg/dL, and his serum bicarbonate and electrolytes were within normal limits. His HIV viral load decreased to 171 copies/mL, and he achieved an undetectable HCV viral load at the end of therapy but has since been lost to follow-up.

**DISCUSSION**

We present a case of AKI in a patient on tenofovir alafenamide and cobicistat worsened by the initiation of SOF/LED. This patient likely had previously undiagnosed chronic kidney disease, with CrCl at antiretroviral therapy (ART) initiation of 50 mL/min, which is likely an overestimate in the setting of his advanced liver disease. His creatinine worsened after initiating EVG/c/FTC/TAF. He then presented with AKI and nonanion gap metabolic acidosis 1 month after initiation of SOF/LED. Ledipasvir is not itself nephrotoxic, but it leads to increased levels of TDF in healthy volunteers [6]. This effect was demonstrated in a case report of AKI precipitated by the addition of SOF-LED to a patient’s stable HIV regimen of TDF-emtricitabine-efavirenz [11]. In that case, the patient’s AKI resolved with discontinuation of TDF and transition to an alternative ART regimen.

Cobicistat inhibits CYP-mediated metabolism of elvitegravir (EVG), leading to increased peak levels and half-life. Cobicistat also increases levels of ledipasvir by a similar mechanism [6, 12]. Thus, when cobicistat, ledipasvir, and TDF are taken together, a double boosting of TDF levels can be expected. The University of Liverpool drug interaction website does not note an interaction between LED and EVG/c/FTC/TAF, which implies that it is a safer alternative than LED and EVG/c/FTC/TDF. Michal and colleagues showed no increased rate of AKI in patients taking TDF vs non-TDF regimens in a real-world cohort of HIV/HCV-infected patients receiving LED/SOF; however, only 1 patient was also taking cobicistat [13].

To date, there are few pharmacologic or empirical data on the expected interaction of SOF/LED and EVG/c/FTC/TAF. This patient had many established risk factors for TDF-related renal toxicity, including age >65 years, impaired baseline renal function, use of other renally cleared medications, and low body mass index [14]. As his creatinine decreased during the hospitalization, signs of proximal tubule injury, a hallmark of...
TDF-related renal injury, became apparent. This clinical syndrome is consistent with tenofovir-induced kidney injury, and a biologically plausible mechanism exists with the aforementioned drug interactions. His renal function improved with discontinuation of his HIV and HCV medications, along with administration of sodium bicarbonate. Other potential contributors to his AKI include his diuretics and angiotensin-converting enzyme inhibitor; however, he had no recent dose changes, presented normotensive without tachycardia, and had no evidence of hypovolemia on physical examination. Alternative causes of AKI including sepsis, hepatorenal syndrome, and ingested nephrotoxins are less likely based on his clinical presentation.

Novick and colleagues published a report of a patient with HIV/HCV on an HIV regimen containing both TAF and cobicistat who developed AKI [15]. Renal biopsy showed mitochondrial abnormalities consistent with the histologic pattern of tenofovir-induced nephrotoxicity. This patient's AKI resolved with discontinuation of TAF but required hemodialysis before improvement. In contrast to our case, the patient was not receiving LED.

Although initial studies of TAF indicate a statistically significant decrease in renal impact compared with TDF, this patient would have been excluded from clinical trials based on his HCV status, baseline CrCl, and his prior ART experience [9]. As TAF becomes ubiquitous in the landscape of treatment for HIV and hepatitis B virus, it is important to note that “less nephrotoxic” does not necessarily mean “not nephrotoxic” and that caution should be taken in using the combination of SOF/LED and EVG/c/FTC/TAF in patients with baseline CKD, low body mass index, older age, and concomitant renally excreted medications.

Acknowledgments

Disclaimer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Financial support. This work was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1 TR002378 and TL1 TR00238 to D.P.S.).

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160:369–79.
2. Chen TY, Ding EL, Seage II GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605–15.
3. AASLD-IDA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 7 November 2017.
4. Naggie S, Cooper C, Saag M, et al; ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705–13.
5. Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of All-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1 -coinfected patients treated in routine practice. Clin Infect Dis 2017; 64:1711–20.
6. Harvoni (Ledipasvir And Sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc; 2017. Available at: https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed 12 August 2017.
7. Antela A, Aguilar C, Compton J, et al. The role of tenofovir alafenamide in future HIV management. HIV Med 2016; 17(Suppl 2):4–16.
8. Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr 2017; 75:211–8.
9. Sax PE, Wohl D, Yin MT, et al; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606–15.
10. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18:56–63.
11. Bunnell KL, Vibhakar S, Glowacki RC, et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy 2016; 36:e148–53.
12. University of Liverpool, United Kingdom. HEP drug interactions. Available at: http://www.hep-druginteractions.org/checker. Accessed 12 August 2017.
13. Michal JL, Rab S, Patel M, et al. Incidence of acute kidney injury in patients coinfected with HIV and hepatitis C virus receiving tenofovir disoproxil fumarate and ledipasvir/sofosbuvir in a real-world, urban, Ryan White clinic. AIDS Res Hum Retroviruses. In press.
14. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57:773–80.
15. Novick TK, Choi MJ, Rosenberg AZ, et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine 2017; 96:e8046.